Analytical Data
-
基因名
HLA-A*02:01&B2M&WT-1(RMFPNAPYL) Tetramer
- Application
-
别名
MHC; WT1; RMF; AWT1; GUD; NPHS4GUD; WAGR; WIT-2; WT33
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A0A140T913 (G25-T305)&P61769
-
表达区间
A0A140T913 (G25-T305)&P61769 (I21-M119)&RMFPNAPYL
-
分子量
260-265 kDa under Non reducing (N)
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/WT-1 (RMFPNAPYL) tetramer recombinant protein is pivotal in cancer immunotherapy and the understanding of immune responses against tumor-associated antigens. WT-1 (Wilms' Tumor 1) is a transcription factor overexpressed in various malignancies, including leukemia and solid tumors, making it an attractive target for immunological intervention. The HLA-A*02:01 molecule, a common human leukocyte antigen (HLA) class I allele, presents the RMFPNAPYL peptide derived from the WT-1 protein, facilitating the recognition and activation of CD8+ cytotoxic T lymphocytes. By constructing a tetrameric complex of HLA-A*02:01, beta-2-microglobulin (B2M), and the WT-1 peptide, researchers can effectively identify and quantify antigen-specific T cells in peripheral blood and tumor tissues, providing insights into the immune landscape of cancers. This research lays the groundwork for developing personalized immunotherapies that harness the body’s own immune system to combat cancer more effectively, and it holds significant promise for enhancing treatment outcomes in patients expressing the HLA-A*02:01 allele.
